An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy

Background: The lack of prospective trial data comparing certain multiple sclerosis (MS) therapies could be addressed with observational research. Objective: The objective of this paper is to investigate outcomes of natalizumab versus fingolimod treatment in an MS cohort using a novel method of pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis 2014-09, Vol.20 (10), p.1381-1390
Hauptverfasser:	Carruthers, Robert L, Rotstein, Dalia L, Healy, Brian C, Chitnis, Tanuja, Weiner, Howard L, Buckle, Guy J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Antibodies, Viral - blood Biomarkers - blood Contrast Media Databases, Factual Disease-Free Survival Female Fingolimod Hydrochloride Humans Immunosuppressive Agents - therapeutic use JC Virus - immunology Kaplan-Meier Estimate Magnetic Resonance Imaging Male Middle Aged Multiple Sclerosis, Relapsing-Remitting - blood Multiple Sclerosis, Relapsing-Remitting - diagnosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Multiple Sclerosis, Relapsing-Remitting - virology Natalizumab Predictive Value of Tests Propylene Glycols - therapeutic use Retrospective Studies Serologic Tests Sphingosine - analogs & derivatives Sphingosine - therapeutic use Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!